Announcements from South Korea (SK) to Denmark (DK) pave the way for further outcomes-based contracting for high-cost oncology drugs

Multi-indication and combination therapies are rapidly influencing the oncology marketplace. Faced with increasing treatment complexity and budget demands, payers across the globe are starting to evolve their approach to contracting.